CureVac B.V. is going public

German biopharmaceutical company from Tübingen develops therapeutic entities based on messenger ribonucleic acid (“mRNA”). The company's lead candidate is Phase 1 stage CV8102 for solid tumors treatment. Cure Vac B.V. is also advancing CV7202, vaccine against rabies, and another one against SARS-CoV-2, both are in Phase 1. Results from the latter should be available next quarter. 

The company’s underwriters will be BofA Securities, Inc., Jefferies LLC and Credit Suisse Securities.
Date of placement: 13.08.2020
Expected IPO price: 14-16$ per common share